SEngine Precision Medicine is a technology company.
SEngine Precision Medicine has raised $10.0M across 1 funding round.
SEngine Precision Medicine has raised $10.0M in total across 1 funding round.
SEngine Precision Medicine is a technology company specializing in precision oncology, focused on revolutionizing cancer diagnostics and treatment by pre-testing drugs on patient-derived tumor organoids grown ex vivo. Their flagship product, the PARIS® Test, is a CLIA-certified diagnostic platform that evaluates a personalized panel of up to 42 oncology drugs on a patient’s tumor cells to predict drug response, integrating cancer genomics with robotics and AI-driven computational tools. This approach addresses the critical problem of low predictive accuracy in current DNA sequencing-based treatments, offering oncologists actionable, personalized treatment options for solid tumors. SEngine serves cancer patients, oncologists, research partners, and pharmaceutical companies, demonstrating growth momentum through commercial availability and strategic collaborations in drug discovery[1][2][3].
Founded in 2015 as a spin-out from the Fred Hutchinson Cancer Research Center, SEngine Precision Medicine was co-founded by Carla Grandori, PhD, MD, leveraging over two decades of research and development in cancer diagnostics and drug discovery. The idea emerged from the need to improve cancer treatment outcomes by moving beyond genomic sequencing alone, which predicts effective treatment only about 15% of the time, toward a functional assay that tests actual drug responses on patient-specific tumor cells. Early traction came from developing the PARIS® Test, which has since become CLIA-certified and commercially available, marking a pivotal moment in translating research into clinical application[1][3].
SEngine Precision Medicine rides the growing trend of precision medicine and functional diagnostics in oncology, addressing the urgent need for personalized cancer treatment beyond genomic data alone. The timing is critical as cancer treatment increasingly demands tailored approaches to improve outcomes and reduce ineffective therapies. Market forces such as advances in organoid technology, AI, and robotics, combined with the expanding oncology drug pipeline, favor SEngine’s platform. By providing a functional assay that integrates with genomic insights, SEngine influences the broader ecosystem by enabling more precise, data-driven clinical decisions and accelerating drug development through strategic partnerships[1][3][5].
Looking ahead, SEngine Precision Medicine is poised to expand its impact by broadening the adoption of the PARIS® Test across oncology centers and deepening collaborations with pharmaceutical companies for drug discovery. Trends shaping their journey include advances in AI, organoid modeling, and the increasing demand for personalized cancer therapies. Their influence may evolve from primarily a diagnostic service to a central player in precision oncology drug development and treatment optimization, potentially setting new standards for functional cancer diagnostics. This trajectory ties back to their core mission of transforming cancer care by delivering truly personalized treatment options based on functional drug response testing[1][3].
SEngine Precision Medicine has raised $10.0M in total across 1 funding round.
SEngine Precision Medicine's investors include WRF Capital.
SEngine Precision Medicine has raised $10.0M across 1 funding round. Most recently, it raised $10.0M Series A in July 2022.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jul 1, 2022 | $10.0M Series A | WRF Capital |